BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009


SEARCH JOBS


Industry
Biotechnology






 Company News
CSL Behring Launches My Access™ Cost Share Program During Hemophilia Awareness Month 3/27/2014 9:19:59 AM    More...
CSL Behring And CSL Plasma Employees Open Their Hearts To Those In Need 2/20/2014 9:53:01 AM    More...
CSL Behring Release: First Patient Enrolled In Phase III Of COMPACT, A Study Of Volume-Reduced Subcutaneous C1-INH For Prevention Of Hereditary Angioedema (HAE) Attacks 2/20/2014 9:51:30 AM    More...
CSL Behring's Kcentra® Receives FDA Approval For Use In Warfarin Reversal In Patients Undergoing Surgery 12/16/2013 7:06:18 AM    More...
CSL Behring Launches Innovative Test Kit Designed To Improve Diagnosis Of Alpha-1 11/26/2013 9:22:51 AM    More...
CSL Behring Launches Innovative Test Kit Designed To Improve Diagnosis Of Alpha-1 11/25/2013 9:47:55 AM    More...
CSL Behring Launches MySource™ at the National Hemophilia Foundation's 65th Annual Meeting 10/3/2013 8:13:01 AM    More...
FDA Approves New Dosing Option for CSL Behring's Hizentra® 9/30/2013 6:34:48 AM    More...
CSL Behring Gains Approval to License Hizentra® in Japan for the Treatment of Primary Immunodeficiency and Secondary Immunodeficiency 9/27/2013 7:01:01 AM    More...
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra® 9/3/2013 10:43:53 AM    More...
12345678910...

//-->